Kyverna Therapeutics (KYTX) Stock Price, News & Analysis

Company Overview

Kyverna Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of engineered T cell therapies for cancer. Leveraging advancements in gene editing and cell therapy, Kyverna is building an off-the-shelf portfolio of allogeneic chimeric antigen receptor (CAR) T and T cell receptor (TCR)-based treatments. The company’s proprietary Nyx platform enables precise, multiplexed genetic modifications designed to enhance the safety, potency and persistence of therapeutic T cells without the need for patient-specific manufacturing.

Kyverna’s lead program, KYX101, is an allogeneic CAR T cell therapy targeting CD19 for the treatment of relapsed or refractory B-cell malignancies and is currently in early-phase clinical evaluation. In addition, the company is advancing KYX102, an allogeneic CAR T product candidate directed against B cell maturation antigen (BCMA) for multiple myeloma, as well as TCR-based constructs aimed at solid tumor antigens. Preclinical data have demonstrated encouraging anti-tumor activity and the potential to address challenges associated with immune evasion and antigen heterogeneity.

Founded in 2023 as a spin-out rooted in pioneering gene-editing research, Kyverna is headquartered in Cambridge, Massachusetts, with research and process development operations in North America and Europe. The company collaborates with leading academic centers and contract development and manufacturing organizations to streamline the translation of its cell therapy candidates into clinical studies. Kyverna has established strategic partnerships to support scalable manufacturing and to facilitate regulatory filings across multiple jurisdictions.

Kyverna’s leadership team is composed of industry veterans drawn from top cell therapy and gene-editing organizations. Chief Executive Officer Gregory Schiffman brings more than two decades of biopharmaceutical experience, while Chief Scientific Officer Dr. Melissa Granger leads the company’s translational research initiatives. Together, the team is dedicated to advancing next-generation allogeneic cell therapies that have the potential to broaden patient access to life-saving treatments.

Key Stats

• Today's Range: $2.52 to $2.83
• 50-Day Range: $2.02 to $3.60
• 52-Week Range: $1.78 to $11.40
• Volume: 374,696 shs
• Average Volume: 384,413 shs
• Market Capitalization: $121.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.50
• Consensus Rating: Buy

Kyverna Therapeutics Stock Analysis - MarketRank™

Kyverna Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 810th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Kyverna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kyverna Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.29) to ($3.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyverna Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyverna Therapeutics is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kyverna Therapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.79% of the float of Kyverna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kyverna Therapeutics has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Kyverna Therapeutics has recently increased by 0.48%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kyverna Therapeutics does not currently pay a dividend.

Dividend Growth

Kyverna Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.79% of the float of Kyverna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kyverna Therapeutics has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Kyverna Therapeutics has recently increased by 0.48%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Kyverna Therapeutics this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for KYTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 18.08% of the stock of Kyverna Therapeutics is held by institutions.

KYTX Stock Analysis - Frequently Asked Questions

How have KYTX shares performed this year?

Kyverna Therapeutics' stock was trading at $3.74 at the beginning of the year. Since then, KYTX stock has decreased by 24.6% and is now trading at $2.82.

How were Kyverna Therapeutics' earnings last quarter?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.21) by $0.18.

When did Kyverna Therapeutics IPO?

Kyverna Therapeutics (KYTX) raised $319 million in an initial public offering (IPO) on Thursday, February 8th 2024. The company issued 14,500,000 shares at $22.00 per share.

Who are Kyverna Therapeutics' major shareholders?

Kyverna Therapeutics' top institutional investors include Kera Capital Partners Inc. (0.98%).
View institutional ownership trends.

How do I buy shares of Kyverna Therapeutics?

Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kyverna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KYTX
• Previous Symbol: NASDAQ:KYTX
• CIK: 1994702
• Web: kyvernatx.com
• Phone: 510-626-8331
• Fax: N/A
• Employees: 96
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kyverna Therapeutics: $18.50
• High Price Target: $33.00
• Low Price Target: $5.00
• Potential Upside/Downside: +556.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.66%
• Return on Assets: -45.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.44
• Quick Ratio: 7.44

Sales & Book Value

• Annual Sales: $7.03 million
• Price / Sales: 17.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.17 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 43,220,000
• Free Float: N/A
• Market Cap: $121.88 million
• Optionable: Optionable
• Beta: 2.95